ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "bone biology"

  • Abstract Number: 1993 • ACR Convergence 2025

    Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout

    Tingting Zhang1, Christian W. Mende2, Ashraf El-Meanawy3, Michael Pillinger4, Kaiding Zhu5, Bradley Marder6 and Brian Lamoreaux7, 1Amgen, Inc., Thousand Oaks, 2University of California San Diego, San Diego, CA, 3Medical College of Wisconsin, Milwaukee, WI, 4New York University Grossman School of Medicine, New York,, NY, 5Amgen, Inc., San Francisco, CA, 6AMGEN, Inc, Denver, CO, 7Amgen, Inc., Deerfield, IL

    Background/Purpose: Gout may increase the risk of cardiovascular events (CVEs) and bone fractures through urate deposition and chronic inflammation1,2. However, the additional effects of uncontrolled…
  • Abstract Number: 1815 • ACR Convergence 2025

    New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential

    Brittney Newby1, Timothy Brandon1, Pamela Weiss2 and E. John Wherry3, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Childrens Hospital of Philadelphia, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Juvenile spondyloarthritis (JSpA) management is hindered by the lack of reliable biomarkers to predict which patients will develop progressive structural changes, such as erosions…
  • Abstract Number: 1142 • ACR Convergence 2025

    Tibial Bone Microstructure and Histomorphometry in Individuals with CPPD

    Sara Tedeschi1, Priyanka Kushwaha2, Muneet Gill2, Julia F. Charles3 and Ellen M. Gravallese4, 1Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, 3Department of Orthopedic Surgery & Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: CPPD has been associated with osteopenia of the metacarpal heads and a 2x increased risk for fracture of the wrist, hip, humerus or pelvis.…
  • Abstract Number: 0872 • ACR Convergence 2025

    Silencing of Schnurri-3 protects from TNF-induced bone loss and is accompanied by upregulation of type I Interferon-Stimulated Genes (ISGs) in osteoblasts.

    Priyanka Kushwaha1, Albert Tai2, Catherine Manning3, Yeon Suk Yang4, Jae-Hyuck Shim4 and Ellen M. Gravallese5, 1Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, 2Department of Immunology, Tufts University School of Medicine, Boston, MA, 3Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 42Department of Medicine/Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA, 5Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Schnurri-3 (SHN3) is an adaptor protein and a negative regulator of osteoblast (OB) function. Its inhibition prevents bone loss and joint erosion in models…
  • Abstract Number: 0867 • ACR Convergence 2025

    NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation

    Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)

    Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of…
  • Abstract Number: 0346 • ACR Convergence 2025

    Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk

    José Rodríguez gago1, Carolina Tornero2, Lina León3, María Luisa González-Casaus3, Luisa Fernanda Giraldo3, Gloria del Peso3, Diego Garrido3, Teresa López3, Mónica Coronado3, María Auxiliadora Bajo4, Sara García3, María Gema Serrano3, Marta Ossorio3, Alejandro Balsa3 and Pilar Aguado3, 1Hospital Universitario La Paz, MADRID, 2Hospital La Paz, Madrid, Spain, 3Hospital Universitario La Paz, Madrid, Spain, 4Hospital Universitario de la Princesa - ISS Princesa, Madrid, Spain

    Background/Purpose: Chronic kidney disease (CKD) is linked to increased vascular comorbidity and fracture risk. This study aims to assess bone status in CKD patients versus…
  • Abstract Number: 0098 • ACR Convergence 2025

    The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:

    Archita Srinath1, Sungsin Jo2, Daniele Mauro3, Mariia Korshko4, Mansi Aparnathi5, Shaghayegh Foroozan Boroojeni6, Tae-Hwan Kim7, Francesco Ciccia8 and Nigil Haroon9, 1University of Toronto, Toronto, ON, Canada, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 3University of Campania, Italy, Naples, Italy, 4UHN, Toronto, ON, Canada, 5Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 6University Health Network/University of Toronto, Toronto, ON, Canada, 7Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8University of Campania, Naples, Italy, 9Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis (AxSpA) is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however over 40% of patients…
  • Abstract Number: 0095 • ACR Convergence 2025

    Effect of JAK Inhibitors on Osteoblast Differentiation

    Toshihiro Tanioka1 and Takeo Isozaki2, 1Graduate School of Pharmacy, Showa Medical University, Shinagawa-ku,Tokyo, Tokyo, Japan, 2Graduate School of Pharmacy, Showa Medical University, Tokyo, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint destruction. Among the therapeutic strategies available, Janus kinase (JAK) inhibitors have…
  • Abstract Number: 2116 • ACR Convergence 2025

    Romosozumab in Multiple Myeloma Patients at High Risk of Fracture

    Giovanni Adami1, Mariana Diz Lopes2, Martina Tinelli2, Angela Bonalumi2, Ombretta Viapiana2 and Maurizio Rossini2, 1University of Verona, Italy, Verona, Italy, 2University of Verona, Verona, Italy

    Background/Purpose: Bone damage is a key feature of multiple myeloma (MM). Romosozumab (ROMO), a sclerostin inhibitor, has dual anabolic and antiresorptive properties and may offer…
  • Abstract Number: 0027 • ACR Convergence 2024

    Cation Channel TRPC1 Regulates Mesenchymal Stem Cell Differentiation and Bone Formation

    Jyoti Yadav1, Shivmurat Yadav2, Jeremy Houser1, Marta Onopuik3, Leonidas Tsiokas3 and Mary Beth Humphrey1, 1University of Oklahoma College of Medicine, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3University of Oklahoma College of Medicine, Oklahoma City

    Background/Purpose: Transient receptor potential canonical 1 (TRPC1), a non-selective cation channel, is characterized by its high permeability to calcium ions (Ca2+), a vital second messenger…
  • Abstract Number: 0068 • ACR Convergence 2024

    Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis

    Yong-Wook Park1, Ki-Jeong Park2, Sungsin Jo3, Tae-Hwan Kim4 and Tae-Jong Kim1, 1Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, 2Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, 3Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton. T helper 17 (Th17) cells play a pivotal role in the…
  • Abstract Number: 0924 • ACR Convergence 2024

    The Cytosolic DNA Sensor AIM2 Regulates Bone Homeostasis Through Bone Progenitor Cell Differentiation

    Jia (Sijia) Chen1, Yukiko Maeda2, Catherine Manning3, Victor Le4, Jae-Hyuck Shim5, Katherine A. Fitzgerald6 and Ellen Gravallese7, 1Brigham and Women's Hospital, Boston, MA, 2Sanofi, worcester, MA, 3Brigham and Women's Hospital, Dedham, MA, 4Digital Biology, Boston, MA, 5University of Massachusetts, Worcester, MA, 6UMass Chan Medical School, Worchester, MA, 7Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Innate sensing pathways and inflammasomes play an important role in autoimmunity and aging. AIM2 is a DNA sensor that triggers inflammasome assembly in myeloid…
  • Abstract Number: 0925 • ACR Convergence 2024

    Macrophages Produce Bone Anabolic Factors in Settings of Inflammation-Induced Bone Formation

    Jia (Sijia) Chen1, Megan Hanlon2, Catherine Manning3, Susan MacLauchlan1, Paul Hoover4, Christian Jacome-Galarza5 and Ellen Gravallese6, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Brigham and Women's Hospital, Dedham, MA, 4Brigham and Women's Hospital, SWAMPSCOTT, MA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Understanding the pathogenesis of inflammation-induced pathologic bone formation remains a significant challenge in spondyloarthritis patients. We thought to uncover the pivotal events driving the…
  • Abstract Number: 0936 • ACR Convergence 2024

    Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis

    Priyanka Kushwaha1, Catherine Manning2, Tadatoshi Sato3, Yeon-Suk Yang3, Jae-Hyuck Shim4 and Ellen Gravallese5, 1Department of Medicine/Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, 2Brigham and Women's Hospital, Dedham, MA, 3Department of Medicine/Division of Rheumatology, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, 4University of Massachusetts, Worcester, MA, 5Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…
  • Abstract Number: 1429 • ACR Convergence 2024

    Association of Bone Erosion and Microarchitecture with Disease Activity and Damage in Sjögren’s Disease

    Andre Franco1, Igor Murai2, Thomas Yang2, Valeria Caparbo3, Virginia Bonoldi2, Diogo Domiciano1, Lissiane Guedes2, Sandra Pasoto1, Camille Figueiredo3 and Rosa M R Pereira3, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2Hospital das Clinicas HCFMUSP, Faculdade de Medicina da USP, São Paulo, SP, Brazil, 3Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, SP, Brazil

    Background/Purpose: Sjögren's disease (SjD) is a chronic multisystem autoimmune condition characterized by sicca syndrome and inflammatory arthralgia, more common in women. Bone involvement can result…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology